Document is current

Article History

Received: 4 September 2024

Accepted: 19 April 2025

First Online: 9 May 2025

Declarations

:

: The ethics committee of Tohoku University Hospital (Approval Number 2019-1-402) and the ethics committees of all other participating hospitals approved this study with an opt-out policy in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. Written informed consent was obtained from patients or their proxies to collect data about functional outcomes at 90 days by distributing questionnaires. This study was conducted in compliance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects and the principles of the Declaration of Helsinki.

: The ethics committee of Tohoku University Hospital (approval number 2019-1-402) and the ethics committees of all other participating hospitals approved this study with an opt-out policy.

: Dr. Miyamoto reports lecturer's fees from Asahi Kasei Pharma, Japan Blood Products Organization, and Chugai Pharmaceutical. Dr. Kawazoe reports lecturer’s fees from Toray Industries Inc. and Asahi Kasei Pharma. Dr. Kyo reports lecturer's fee from TXP Medical. Dr. Masaki Takahashi reports lecture's fees from Japan Blood Products Organization and Eisai Co., Ltd.. Dr. Gaku Takahashi reports lecturer’s fees from Toray Industries Inc. and Asahi Kasei Pharma. and JB Pharma. Dr. Hanajima reports lecturer's fee from Toray Industries Inc.. Dr Morimoto reports lecturer's fees from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Pfizer, Tsumura and UCB; manuscript fee from Pfizer; advisory board for GlaxoSmithKline, Novartis and Teijin.